• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[Iatrogenic pulmonary artery hypertension].

作者信息

Weitzenblum E, Kessler R, Chaouat A

机构信息

Service de Pneumologie, CHRU de Strasbourg, Hôpital de Hautepierre.

出版信息

Rev Mal Respir. 1996;13(2):133-9.

PMID:8711232
Abstract

Primary pulmonary arterial hypertension (PPH) is a rare disorder with a predilection for young subjects (most commonly of 20-40 years) and of the female sex. The prognosis is very poor because the average life expectancy is of the order of two to three years from the time of diagnosis. Since the epidemic of PPH observed in Switzerland, Austria and Germany in the years between 1968 and 1970, following the arrival of a derivative of amphetamine, Aminorex, it was realised that certain medications, notably appetite suppressants, might play an initiating role. More recently, fenfluramine and dexfenfluramine have been incriminated: in a significant statistic of A-beclere's team, around 20% of cases of PPH were observed in patients who had taken fenfluramine or dexfenfluranime for more than three months. A very recent case-control study has shown that any use of anorexic drugs (mainly fenfluramine derivatives) was associated with an increased risk of PPH (odds ratio: 6/1), and particularly when the duration of treatment exceeds 3 months. Outside the group of appetite suppressants few medications are capable of favouring the development of PPH, the cases are sporadic and the relationship between cause and effect is hardly established.

摘要

相似文献

1
[Iatrogenic pulmonary artery hypertension].
Rev Mal Respir. 1996;13(2):133-9.
2
Temporal trends and drug exposures in pulmonary hypertension: an American experience.肺动脉高压的时间趋势与药物暴露:美国的经验
Am Heart J. 2006 Sep;152(3):521-6. doi: 10.1016/j.ahj.2006.02.020.
3
A population-based study of appetite-suppressant drugs and the risk of cardiac-valve regurgitation.一项基于人群的食欲抑制药物与心脏瓣膜反流风险的研究。
N Engl J Med. 1998 Sep 10;339(11):719-24. doi: 10.1056/NEJM199809103391102.
4
[Drug induced pulmonary hypertension].
Nihon Rinsho. 2001 Jun;59(6):1197-202.
5
[Chronic pulmonary hypertension of vascular origin, plexogenic pulmonary arteriopathy and the appetite depressant aminorex: addenda to an epidemic].[血管源性慢性肺动脉高压、丛状肺血管病与食欲抑制剂阿米雷司:一种流行病的补遗]
Schweiz Med Wochenschr. 1985 Jun 8;115(23):782-9contd.
6
Aminorex, dexfenfluramine, and primary pulmonary hypertension.
J Clin Epidemiol. 1998 Apr;51(4):361-4. doi: 10.1016/s0895-4356(97)00289-8.
7
Appetite-suppressant drugs and the risk of primary pulmonary hypertension. International Primary Pulmonary Hypertension Study Group.食欲抑制药物与原发性肺动脉高压风险。国际原发性肺动脉高压研究组
N Engl J Med. 1996 Aug 29;335(9):609-16. doi: 10.1056/NEJM199608293350901.
8
[Primary vascular pulmonary hypertension and appetite depressants].
Med Klin. 1971 Mar 12;66(11):386-90.
9
Appetite suppressants and pulmonary hypertension: a long-term risk.食欲抑制剂与肺动脉高压:一项长期风险。
Prescrire Int. 2006 Oct;15(85):183.
10
Anorexigens and pulmonary hypertension in the United States: results from the surveillance of North American pulmonary hypertension.
Chest. 2000 Mar;117(3):870-4. doi: 10.1378/chest.117.3.870.